Investor Relations

AgeneBio is dedicated to developing the first and only treatments designed to address hippocampal overactivity.

Investment Thesis

Novel Pipeline for Neurological and Psychiatric Diseases Addressing Significant Unmet Medical Needs

Phase 3 ready program: AGB101

  • Targets large population with aMCI* due to Alzheimer’s disease
    • No treatments exist for the more than 5 million patients
  • Positive Phase 2 trial results
    • First and only product candidate addressing brain network imbalance that leads to memory loss and brain atrophy
  • Novel, extended release once-a-day medication
  • Extensive intellectual property protection and coverage

Late discovery stage new chemical entity program

  • GABA a5 positive allosteric modulator program
  • Applicability to multiple cognition-related indications with no current options including Alzheimer’s disease, schizophrenia, and autism
  • Ready to move in to human clinical trials by early 2018

Investor Materials

AgeneBio Corporate Deck-December 2016



Neuroscience BioPartnering & Investment Forum
February 23, 2016
New York, NY

BIO CEO & Investor Conference
February 8-9, 2016
New York, NY

Future of Innovation in Medicine Conference
December 3-4, 2015
Seattle, WA

Therapeutic Area Partnership Conference
November 18-20, 2015
Boston, MA

BIO Investor Forum
October 20-21, 2015
San Francisco, CA

Clinical Trials on Alzheimer’s Disease
November 5-7, 2015
Barcelona, Spain

Recent News

AgeneBio to Present at Neuroscience BioPartnering & Investment Forum
February 17, 2016

AgeneBio to Present at BIO CEO & Investor Conference
February 2, 2016

AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website
December 15, 2015

AgeneBio Appoints Richard Mohs, PhD, Vice President of Clinical Development
December 8, 2015

More news releases

AgeneBio in the news

Email Alerts

Sign up for email alerts here.

Investor Contact

Jerry McLaughlin
President and CEO

Media Contacts

Jennifer Guinan
Sage Strategic Marketing

Hilary Lefebvre